Wang Gang, former chief scientist of CDE, transferred from Yaoming biology to Junshi biology!

Jun shibio announced on August 20 that he appointed Dr Wang Gang as senior vice president and chief quality officer of industrial affairs to be fully responsible for the production quality and related work of the company Recent photos of Dr Wang Gang Dr Wang Gang has been engaged in the pharmaceutical industry for more than 30 years He has more than 20 years of experience in the field of cGMP (quality management standard for pharmaceutical production) and biological products, including cell and gene therapy product review, production, pre approval inspection, cGMP compliance inspection, and supervision He once worked in the former CFDA and FDA ）, chief scientist in charge of compliance and inspection of CFDA drug review center (CDE), assistant director of FDA office in China, etc After many years of working in the government regulatory sector, Dr Wang Gang has transformed into an enterprise Before joining Junshi biology, he was vice president of Quality Department of YaoMing biology in Shanghai, responsible for the quality and global supervision of YaoMing biology Dr Wang Gang joined in Junshi biology, and will lead the team to focus on the construction of an international production quality management system to meet the growing demand for production capacity and international market expansion Dr Li Ning, chief executive officer of Junshi biology, Dr Li Ning, chief executive officer of Junshi biology: "China's bio innovative drugs have great potential The policy support of the Chinese government and the speed of manufacturing in China make us confident to make innovative drug companies fast, well and strong." Dr Li Ning, chief executive officer of Jushi, said, "we believe that the participation of Dr Wang Gang will have a profound impact and promotion on the overall quality management of Jushi We hope that with his help, Junshi biological's production quality system can step up to a new level, speed up our steps towards the world with higher efficiency, and give back to the vast number of patients we trust with better quality " Dr Wang Gang: "Junshi bio is positioned as a world-class biopharmaceutical enterprise The emphasis on the production quality system shows me the global pattern of Chinese enterprises It is also what I want to do most to help domestic enterprises to improve the production quality system of biopharmaceutical products to the international level, go to the international market and become the world's leading innovative pharmaceutical enterprise " Wang Gang said Wang Gang graduated from Nanjing University, majoring in biochemistry, and received his doctorate in pharmacology and toxicology from Dartmouth Medical School After graduation, he worked as a postdoctoral researcher in the field of tumor immunotherapy at the National Cancer Center (NCI) of the National Institutes of Health (NIH), and then worked as an assistant professor and project leader at MD Anderson Cancer Center of the University of Texas About Junshi biology, Junshi biology was founded in December 2012 by a number of teams with rich experience in transnational scientific and technological achievements transformation and industry, graduated from famous universities in China and the United States Junshi biology focuses on the development and industrialization of monoclonal antibody drugs and other therapeutic protein drugs It is the first Chinese company to obtain the market approval of anti PD-1 monoclonal antibody nmpa, the first Chinese company to obtain the ind application approval of nmpa for anti PCSK9 monoclonal antibody and anti BLyS monoclonal antibody, and the first Chinese company to obtain the ind application approval of anti BTLA blocking antibody in the world in the US FDA 。 At present, it has more than 1000 employees in the world, distributed in San Francisco and Maryland, Shanghai, Suzhou, Beijing and Guangzhou, China.